Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Sell
46
AUTL Quote, Financials, Valuation and Earnings
Last price:
$1.82
Seasonality move
:
-20.08%
Day range:
$1.80 - $1.97
52-week range:
$1.11 - $2.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
9.40x
P/B ratio:
2.42x
Volume:
2.1M
Avg. volume:
2.5M
1-year change:
-24.9%
Market cap:
$481.7M
Revenue:
$10.1M
EPS (TTM):
-$0.84
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AUTL
Autolus Therapeutics Plc
|
$24.3M | -$0.40 | 84624.25% | -288.08% | $9.63 |
|
BCYC
Bicycle Therapeutics Plc
|
$7.1M | -$0.94 | 92.62% | -25.75% | $21.50 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
MREO
Mereo BioPharma Group Plc
|
$7.1M | -$0.01 | -100% | -74.53% | $3.72 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AUTL
Autolus Therapeutics Plc
|
$1.81 | $9.63 | $481.7M | -- | $0.00 | 0% | 9.40x |
|
BCYC
Bicycle Therapeutics Plc
|
$6.64 | $21.50 | $460.6M | -- | $0.00 | 0% | 16.23x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$2.35 | $17.94 | $2M | -- | $0.00 | 0% | 0.73x |
|
MREO
Mereo BioPharma Group Plc
|
$0.38 | $3.72 | $61.1M | -- | $0.00 | 0% | 120.03x |
|
NCNA
NuCana Plc
|
$3.60 | $104.00 | $15M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 2.916 | 74.96% | 4.83x |
|
BCYC
Bicycle Therapeutics Plc
|
1.04% | 1.504 | 1.21% | 9.36x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.608 | -- | 1.20x |
|
MREO
Mereo BioPharma Group Plc
|
0.85% | 1.603 | 0.12% | 8.09x |
|
NCNA
NuCana Plc
|
0.52% | -0.467 | 0.95% | 4.03x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
BCYC
Bicycle Therapeutics Plc
|
$9.9M | -$72.9M | -33.96% | -34.37% | -624.9% | -$71.3M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
MREO
Mereo BioPharma Group Plc
|
-- | -$10.3M | -67.41% | -70.81% | -2099.86% | -$7.3M |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
Autolus Therapeutics Plc vs. Competitors
-
Which has Higher Returns AUTL or BCYC?
Bicycle Therapeutics Plc has a net margin of -373.3% compared to Autolus Therapeutics Plc's net margin of -503.67%. Autolus Therapeutics Plc's return on equity of -59.51% beat Bicycle Therapeutics Plc's return on equity of -34.37%.
Company Gross Margin Earnings Per Share Invested Capital AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M BCYCBicycle Therapeutics Plc85.04% -$0.85 $625M -
What do Analysts Say About AUTL or BCYC?
Autolus Therapeutics Plc has a consensus price target of $9.63, signalling upside risk potential of 432.23%. On the other hand Bicycle Therapeutics Plc has an analysts' consensus of $21.50 which suggests that it could grow by 223.8%. Given that Autolus Therapeutics Plc has higher upside potential than Bicycle Therapeutics Plc, analysts believe Autolus Therapeutics Plc is more attractive than Bicycle Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings AUTLAutolus Therapeutics Plc9 0 0 BCYCBicycle Therapeutics Plc6 4 0 -
Is AUTL or BCYC More Risky?
Autolus Therapeutics Plc has a beta of 2.012, which suggesting that the stock is 101.185% more volatile than S&P 500. In comparison Bicycle Therapeutics Plc has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.42%.
-
Which is a Better Dividend Stock AUTL or BCYC?
Autolus Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics Plc pays -- of its earnings as a dividend. Bicycle Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AUTL or BCYC?
Autolus Therapeutics Plc quarterly revenues are $21.1M, which are larger than Bicycle Therapeutics Plc quarterly revenues of $11.7M. Autolus Therapeutics Plc's net income of -$78.6M is lower than Bicycle Therapeutics Plc's net income of -$58.7M. Notably, Autolus Therapeutics Plc's price-to-earnings ratio is -- while Bicycle Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics Plc is 9.40x versus 16.23x for Bicycle Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AUTLAutolus Therapeutics Plc9.40x -- $21.1M -$78.6M BCYCBicycle Therapeutics Plc16.23x -- $11.7M -$58.7M
-
Which has Higher Returns AUTL or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -373.3% compared to Autolus Therapeutics Plc's net margin of --. Autolus Therapeutics Plc's return on equity of -59.51% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About AUTL or BDRX?
Autolus Therapeutics Plc has a consensus price target of $9.63, signalling upside risk potential of 432.23%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 7468.14%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Autolus Therapeutics Plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Autolus Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings AUTLAutolus Therapeutics Plc9 0 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is AUTL or BDRX More Risky?
Autolus Therapeutics Plc has a beta of 2.012, which suggesting that the stock is 101.185% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.952, suggesting its less volatile than the S&P 500 by 4.8%.
-
Which is a Better Dividend Stock AUTL or BDRX?
Autolus Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics Plc pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AUTL or BDRX?
Autolus Therapeutics Plc quarterly revenues are $21.1M, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. Autolus Therapeutics Plc's net income of -$78.6M is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, Autolus Therapeutics Plc's price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics Plc is 9.40x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AUTLAutolus Therapeutics Plc9.40x -- $21.1M -$78.6M BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns AUTL or MREO?
Mereo BioPharma Group Plc has a net margin of -373.3% compared to Autolus Therapeutics Plc's net margin of -2923.31%. Autolus Therapeutics Plc's return on equity of -59.51% beat Mereo BioPharma Group Plc's return on equity of -70.81%.
Company Gross Margin Earnings Per Share Invested Capital AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M MREOMereo BioPharma Group Plc14% -$0.04 $47M -
What do Analysts Say About AUTL or MREO?
Autolus Therapeutics Plc has a consensus price target of $9.63, signalling upside risk potential of 432.23%. On the other hand Mereo BioPharma Group Plc has an analysts' consensus of $3.72 which suggests that it could grow by 868.23%. Given that Mereo BioPharma Group Plc has higher upside potential than Autolus Therapeutics Plc, analysts believe Mereo BioPharma Group Plc is more attractive than Autolus Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings AUTLAutolus Therapeutics Plc9 0 0 MREOMereo BioPharma Group Plc4 2 0 -
Is AUTL or MREO More Risky?
Autolus Therapeutics Plc has a beta of 2.012, which suggesting that the stock is 101.185% more volatile than S&P 500. In comparison Mereo BioPharma Group Plc has a beta of 0.358, suggesting its less volatile than the S&P 500 by 64.214%.
-
Which is a Better Dividend Stock AUTL or MREO?
Autolus Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics Plc pays -- of its earnings as a dividend. Mereo BioPharma Group Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AUTL or MREO?
Autolus Therapeutics Plc quarterly revenues are $21.1M, which are larger than Mereo BioPharma Group Plc quarterly revenues of --. Autolus Therapeutics Plc's net income of -$78.6M is lower than Mereo BioPharma Group Plc's net income of -$7M. Notably, Autolus Therapeutics Plc's price-to-earnings ratio is -- while Mereo BioPharma Group Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics Plc is 9.40x versus 120.03x for Mereo BioPharma Group Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AUTLAutolus Therapeutics Plc9.40x -- $21.1M -$78.6M MREOMereo BioPharma Group Plc120.03x -- -- -$7M
-
Which has Higher Returns AUTL or NCNA?
NuCana Plc has a net margin of -373.3% compared to Autolus Therapeutics Plc's net margin of --. Autolus Therapeutics Plc's return on equity of -59.51% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About AUTL or NCNA?
Autolus Therapeutics Plc has a consensus price target of $9.63, signalling upside risk potential of 432.23%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 577677.78%. Given that NuCana Plc has higher upside potential than Autolus Therapeutics Plc, analysts believe NuCana Plc is more attractive than Autolus Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings AUTLAutolus Therapeutics Plc9 0 0 NCNANuCana Plc0 1 0 -
Is AUTL or NCNA More Risky?
Autolus Therapeutics Plc has a beta of 2.012, which suggesting that the stock is 101.185% more volatile than S&P 500. In comparison NuCana Plc has a beta of 1.602, suggesting its more volatile than the S&P 500 by 60.248%.
-
Which is a Better Dividend Stock AUTL or NCNA?
Autolus Therapeutics Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Autolus Therapeutics Plc pays -- of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AUTL or NCNA?
Autolus Therapeutics Plc quarterly revenues are $21.1M, which are larger than NuCana Plc quarterly revenues of --. Autolus Therapeutics Plc's net income of -$78.6M is lower than NuCana Plc's net income of -$378.9K. Notably, Autolus Therapeutics Plc's price-to-earnings ratio is -- while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Autolus Therapeutics Plc is 9.40x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AUTLAutolus Therapeutics Plc9.40x -- $21.1M -$78.6M NCNANuCana Plc-- -- -- -$378.9K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
65
RGC alert for Jan 10
Regencell Bioscience Holdings Ltd. [RGC] is up 10.55% over the past day.
Sell
50
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
